CDSCO Examines Risks of Brand Name Extensions Across Different Drug Formulations
CDSCO has invited stakeholder feedback on drug brand name extensions amid concerns over therapeutic confusion and patient safety, with comments due by 17 July 2026.
patient safety
Use of “Dr.” by Physiotherapists Under Examination: DGHS Directive Withdrawn for Review
DGHS directive restricting physiotherapists from using the prefix “Dr.” has been withdrawn for further review following legal challenges and professional objections.
Delhi High Court upholds Centre decision to bring all medical devices under the ambit of ‘drug’ under Drugs and Cosmetics Act, 1940
The larger public interest, which concerns patient safety, requires that all medical devices be brought within a regulatory regime. One cannot quibble with the intent, purpose and object with which the impugned notifications have been issued.